Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Safety and immunogenicity against ancestral, Delta and Omicron virus variants following a booster dose of an inactivated whole-virus COVID-19 vaccine (VLA2001): Interim analysis of an open-label extension of the randomized, controlled, phase 3 COV-COMPARE trial.
Taucher C, Lazarus R, Dellago H, Maurer G, Weisova P, Corbic-Ramljak I, Dubischar K, Lilja A, Eder-Lingelbach S, Hochreiter R, Jaramillo JC, Junker H, Krammer M, Pusic P, Querton B, Larcher-Senn J, Hoffmann M, Pöhlmann S, Finn A; Valneva Phase 3 Booster Trial Group. Taucher C, et al. Among authors: weisova p. J Infect. 2023 Sep;87(3):242-254. doi: 10.1016/j.jinf.2023.06.022. Epub 2023 Jul 3. J Infect. 2023. PMID: 37406777 Clinical Trial.
Immunogenicity and safety of an inactivated whole-virus COVID-19 vaccine (VLA2001) compared with the adenoviral vector vaccine ChAdOx1-S in adults in the UK (COV-COMPARE): interim analysis of a randomised, controlled, phase 3, immunobridging trial.
Lazarus R, Querton B, Corbic Ramljak I, Dewasthaly S, Jaramillo JC, Dubischar K, Krammer M, Weisova P, Hochreiter R, Eder-Lingelbach S, Taucher C, Finn A; Valneva phase 3 trial group. Lazarus R, et al. Among authors: weisova p. Lancet Infect Dis. 2022 Dec;22(12):1716-1727. doi: 10.1016/S1473-3099(22)00502-3. Epub 2022 Sep 5. Lancet Infect Dis. 2022. PMID: 36075233 Free PMC article. Clinical Trial.
AMPK-regulated miRNA-210-3p is activated during ischaemic neuronal injury and modulates PI3K-p70S6K signalling.
Pfeiffer S, Tomašcová A, Mamrak U, Haunsberger SJ, Connolly NMC, Resler A, Düssmann H, Weisová P, Jirström E, D'Orsi B, Chen G, Cremona M, Hennessy BT, Plesnila N, Prehn JHM. Pfeiffer S, et al. Among authors: weisova p. J Neurochem. 2021 Nov;159(4):710-728. doi: 10.1111/jnc.15347. Epub 2021 Mar 18. J Neurochem. 2021. PMID: 33694332 Free article.
Humanized tau antibodies promote tau uptake by human microglia without any increase of inflammation.
Zilkova M, Nolle A, Kovacech B, Kontsekova E, Weisova P, Filipcik P, Skrabana R, Prcina M, Hromadka T, Cehlar O, Rolkova GP, Maderova D, Novak M, Zilka N, Hoozemans JJM. Zilkova M, et al. Among authors: weisova p. Acta Neuropathol Commun. 2020 May 29;8(1):74. doi: 10.1186/s40478-020-00948-z. Acta Neuropathol Commun. 2020. PMID: 32471486 Free PMC article.
Therapeutic antibody targeting microtubule-binding domain prevents neuronal internalization of extracellular tau via masking neuron surface proteoglycans.
Weisová P, Cehlár O, Škrabana R, Žilková M, Filipčík P, Kováčech B, Prčina M, Wojčiaková Ľ, Fialová Ľ, Smolek T, Kontseková E, Žilka N, Novák M. Weisová P, et al. Acta Neuropathol Commun. 2019 Aug 7;7(1):129. doi: 10.1186/s40478-019-0770-y. Acta Neuropathol Commun. 2019. PMID: 31391090 Free PMC article.
18 results